Clinical trials offer patients the very latest in cancer care, while giving physicians and researchers the opportunity to study the effectiveness of the treatment. The Capital Health Center for Oncology participates in many National Cancer Institute, University and Pharmaceutical Phase III clinical trials. Our oncologists and research nurses carefully review the study criteria, potential benefits, risks, and other considerations with eligible patients before enrolling in a clinical study. The staff in our Clinical Research Department will carefully monitor you throughout the clinical trial and answer any questions you may have about the trial.
Please contact Linda Andrzejewski, RN, CCRP at 609-537-7042 or e-mail her at email@example.com for more information.
Active clinical trials currently being offered:
SWOG 1007 A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
RTOG 1203 A Randomized Phase III study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)
Establishing an anticipatory model for anxiety and depression through a screening tool for first-time radiation oncology patients
The Capital Health CyberKnife® Center continues to enhance clinical care through research by providing the most current treatment options in radiotherapy and CyberKnife radiosurgery. We currently participate in several clinical trials initiated at leading academic medical centers throughout the country and are in the process of initiating novel investigations involving the use of the CyberKnife with the hope of meeting the needs of our community and improving our patients’ cancer outcomes.
Current Active Clinical Trials:
- CK Brain Mets-01 - A Phase II consensus multi-institutional trial of CyberKnife Radiosurgery to the operative cavity in patients with resected brain metastases. (Clinical Trial)
This clinical trial is open to all patients who have brain metastases, who are older than 18 years of age and have not previously received whole brain radiation. The standard treatment for patients who have tumor metastasis to the brain may include surgery and various forms of radiation therapy. Unfortunately, in the past, these treatments were not curative and could be toxic. This study is being done to evaluate a novel CyberKnife treatment combination for one to three metastatic cancerous tumors in the brain. The protocol involves surgery followed by focused beams of CyberKnife radiation. If you think you may qualify for this trial or have any further questions, please ask our radiation oncologist for more explanation about this study.
- RTOG 0631 - Phase II/III study of image-guided radiosurgery/SBRT for localized spine metastasis